CD274 and neoplasm: Apart from targeting different or other checkpoints than CTLA-4 or PD-1/PD-L1 combinations with classic and newer cancer therapies including radiotherapy, chemotherapy and targeted therapy as well as other immunotherapies such as tumor vaccines and adoptive cell therapy are going to attract interest.